SCHEMBL6955491

SCHEMBL6955491

CCCCCCC=CCCCCCCCC(=O)OCN1C(=O)C(c2cn(C)c3ccccc23)=C(c2cn(C)c3cc([N+](=O)[O-])ccc23)C1=O

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CCNT1 O60563 4/20 0.42
CDK9 P50750 4/20 0.42
CCNA2 P20248 1/20 0.42
CDK2 P24941 1/20 0.42
PRKCA P17252 1/20 0.39
PRKCE Q02156 1/20 0.39
RASGRP3 Q8IV61 1/20 0.39
PSEN1 P49768 2/20 0.38
PSEN2 P49810 2/20 0.38
APH1B Q8WW43 2/20 0.38
NCSTN Q92542 2/20 0.38
APH1A Q96BI3 2/20 0.38
PSENEN Q9NZ42 2/20 0.38
MAPT P10636 1/20 0.38
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6946616 0.95 CCNT1 (0.45) CCNT1CDK9CCNA2CDK2PRKCA
SCHEMBL6956384 0.88 CCNT1 (0.46) CCNT1CDK9CCNA2CDK2
SCHEMBL7164524 0.85 CCNT1 (0.47) CCNT1CDK9CCNA2CDK2
SCHEMBL7500940 0.82 CCNT1 (0.46) CCNT1CDK9CCNA2CDK2
SCHEMBL6947835 0.80 CCNT1 (0.44) CCNT1CDK9CCNA2CDK2RASGRP3
SCHEMBL6950505 0.79 CCNT1 (0.42) CCNT1CDK9CCNA2CDK2MAPT
SCHEMBL7508601 0.79 CCNT1 (0.47) CCNT1CDK9CCNA2CDK2
SCHEMBL6956508 0.79 CCNT1 (0.42) CCNT1CDK9CCNA2CDK2ALDH1A1
SCHEMBL6425124 0.79 CCNT1 (0.45) CCNT1CDK9CCNA2CDK2PSEN1
SCHEMBL6425123 0.79 CCNT1 (0.45) CCNT1CDK9CCNA2CDK2PSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1224181-B1 SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER HOFFMANN LA ROCHE (CH) 2003-12-03 EP disclosed
US-6559164-B1 These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. HOFFMANN-LA ROCHE INC. 2003-05-06 US disclosed
EP-1224181-A1 SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2002-07-24 EP disclosed
WO-2001027106-A1 SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER F. HOFFMANN-LA ROCHE AG (CH) 2001-04-19 WO disclosed